Compile Data Set for Download or QSAR
maximum 50k data
Found 736 with Last Name = 'song' and Initial = 'f'
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123630(US8748624, 144)
Affinity DataKi:  12.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50525881(CHEMBL4513792)
Affinity DataKi:  14nMAssay Description:Inhibition of human full length GCGR transfected in HEK293 cells assessed as reduction in glucagon-induced cAMP response by LANCE TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123549(US8748624, 35)
Affinity DataKi:  14.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123582(US8748624, 74)
Affinity DataKi:  14.9nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123633(US8748624, 147)
Affinity DataKi:  15.7nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123637(US8748624, 151)
Affinity DataKi:  16.5nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123556(US8748624, 42)
Affinity DataKi:  16.5nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123559(US8748624, 51)
Affinity DataKi:  16.8nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123557(US8748624, 43)
Affinity DataKi:  17.2nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123651(US8748624, 174)
Affinity DataKi:  18.3nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123558(US8748624, 44)
Affinity DataKi:  18.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123634(US8748624, 148)
Affinity DataKi:  18.7nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123575(US8748624, 67)
Affinity DataKi:  18.8nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50522731(CHEMBL4441980)
Affinity DataKi:  19nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123544(US8748624, 30)
Affinity DataKi:  19.3nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123593(US8748624, 92)
Affinity DataKi:  19.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123535(US8748624, 21)
Affinity DataKi:  19.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123581(US8748624, 73)
Affinity DataKi:  19.5nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123560(US8748624, 52)
Affinity DataKi:  19.9nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123644(US8748624, 158)
Affinity DataKi:  20nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123580(US8748624, 72)
Affinity DataKi:  20.3nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123555(US8748624, 41)
Affinity DataKi:  20.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123647(US8748624, 170)
Affinity DataKi:  20.7nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123599(US8748624, 102)
Affinity DataKi:  21.3nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123547(US8748624, 33)
Affinity DataKi:  21.3nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123541(US8748624, 27)
Affinity DataKi:  21.5nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123626(US8748624, 140)
Affinity DataKi:  21.5nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50522737(CHEMBL4469925)
Affinity DataKi:  22nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50525882(CHEMBL4472098)
Affinity DataKi:  22nMAssay Description:Inhibition of human full length GCGR transfected in HEK293 cells assessed as reduction in glucagon-induced cAMP response by LANCE TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50525891(CHEMBL4463908)
Affinity DataKi:  22nMAssay Description:Inhibition of human full length GCGR transfected in HEK293 cells assessed as reduction in glucagon-induced cAMP response by LANCE TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123545(US8748624, 31)
Affinity DataKi:  22.1nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123522(US8748624, 7)
Affinity DataKi:  22.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123552(US8748624, 38)
Affinity DataKi:  22.5nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123571(US8748624, 63)
Affinity DataKi:  22.6nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123600(US8748624, 103)
Affinity DataKi:  22.9nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50525890(CHEMBL4582082)
Affinity DataKi:  23nMAssay Description:Inhibition of human full length GCGR transfected in HEK293 cells assessed as reduction in glucagon-induced cAMP response by LANCE TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123551(US8748624, 37)
Affinity DataKi:  23.2nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123604(US8748624, 107)
Affinity DataKi:  23.7nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123548(US8748624, 34)
Affinity DataKi:  23.8nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123605(US8748624, 108)
Affinity DataKi:  23.9nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123585(US8748624, 78)
Affinity DataKi:  24nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123586(US8748624, 79)
Affinity DataKi:  24nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123652(US8748624, 175)
Affinity DataKi:  24.2nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123584(US8748624, 77)
Affinity DataKi:  24.2nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50525884(CHEMBL4589676)
Affinity DataKi:  25nMAssay Description:Inhibition of human full length GCGR transfected in HEK293 cells assessed as reduction in glucagon-induced cAMP response by LANCE TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123546(US8748624, 32)
Affinity DataKi:  25.1nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123536(US8748624, 22)
Affinity DataKi:  25.2nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123601(US8748624, 104)
Affinity DataKi:  25.4nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123537(US8748624, 23)
Affinity DataKi:  26.1nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucagon receptor(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM123603(US8748624, 106)
Affinity DataKi:  26.1nMpH: 7.4Assay Description:The binding assay was performed by a filtration method in a 384 well format. Membranes at a final protein concentration of 6 μg/well were incuba...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 736 total ) | Next | Last >>
Jump to: